Candidate biomarkers in heart failure with reduced and preserved ejection fraction
Standard
Candidate biomarkers in heart failure with reduced and preserved ejection fraction. / Sinning, Christoph; Zengin, Elvin; Zeller, Tanja; Schnabel, Renate B; Blankenberg, Stefan; Westermann, Dirk.
in: BIOMARKERS, Jahrgang 20, Nr. 4, 2015, S. 258-265.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Candidate biomarkers in heart failure with reduced and preserved ejection fraction
AU - Sinning, Christoph
AU - Zengin, Elvin
AU - Zeller, Tanja
AU - Schnabel, Renate B
AU - Blankenberg, Stefan
AU - Westermann, Dirk
PY - 2015
Y1 - 2015
N2 - CONTEXT: Patients presenting with heart failure symptoms are categorized into heart failure (HF) with reduced and preserved ejection fraction.OBJECTIVE: Aim is to investigate the additional use of candidate biomarkers to characterize patients with either sub-type of HF.METHODS: Literature search was conducted in the electronic databases MEDLINE and Cochrane Central Register of Controlled Trials from inception through November 2014.RESULTS: The results of 47 diseased and general population cohorts were included.CONCLUSION: Current studies could outline the additional use of candidate biomarkers especially GDF-15, MR-proADM and high-sensitive determined troponin, although major outcome studies are still missing.
AB - CONTEXT: Patients presenting with heart failure symptoms are categorized into heart failure (HF) with reduced and preserved ejection fraction.OBJECTIVE: Aim is to investigate the additional use of candidate biomarkers to characterize patients with either sub-type of HF.METHODS: Literature search was conducted in the electronic databases MEDLINE and Cochrane Central Register of Controlled Trials from inception through November 2014.RESULTS: The results of 47 diseased and general population cohorts were included.CONCLUSION: Current studies could outline the additional use of candidate biomarkers especially GDF-15, MR-proADM and high-sensitive determined troponin, although major outcome studies are still missing.
KW - Adrenomedullin/analysis
KW - Biomarkers/analysis
KW - Growth Differentiation Factor 15/analysis
KW - Heart Failure/diagnosis
KW - Humans
KW - Peptide Fragments/analysis
KW - Prognosis
KW - Protein Precursors/analysis
KW - Sensitivity and Specificity
KW - Stroke Volume
U2 - 10.3109/1354750X.2015.1068856
DO - 10.3109/1354750X.2015.1068856
M3 - SCORING: Review article
C2 - 26301884
VL - 20
SP - 258
EP - 265
JO - BIOMARKERS
JF - BIOMARKERS
SN - 1354-750X
IS - 4
ER -